A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and With Normal Renal Function

Inclusion Criteria:

- Patients having histologically-proven solid tumors, who are either refractory to
standard chemotherapy;

- Patients whom chemotherapy with an investigaional agent in combination with
docetaxel, or paclitaxel + carboplatin is appropriate;

- Creatinine clearance according to Cockcroft-Gault formula : Normal > 80 mL/min, Mild
50-80 mL/min, Moderate 30-<50 mL/min;

- A minimum of 4 weeks must have elapsed since the last treatment with other cancer
therapies;

- Potassium, calcium, magnesium and phosphorus values within the normal range;

- Body Mass Index (BMI) must be within the range of 18 and 30

Exclusion Criteria:

- Patients having CNS metastases, must have a CT or MRI of the brain performed to rule
out CNS metastases;

- Patients with leptomeningeal disease metastases;

- Radiotherapy
- Major surgery
- Administration of CYP1A2 and CYP3A4/5 enzyme inducing or inhibiting drugs within 14
days prior to starting study drug;

Other protocol-defined inclusion/exclusion criteria may apply